Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy)

Onivyde I.V. infusion 43 mg General Drug Use-Results Survey (Unresectable pancreatic cancer after disease progression following cancer chemotherapy) - Onivyde General Drug Use-Results Survey (Pancreatic cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041015

Enrollment

300

Registered

2020-07-07

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are administered Onivyde for the first time to Unresectable pancreatic cancer after disease progression following cancer chemotherapy per standard clinical practice and per prescribing information. In addition, patients who are given consent to participation in the survey.

Exclusion criteria

Exclusion criteria: No given consent to participation in the survey.

Design outcomes

Primary

Measure	Time frame
Overall incidence of each ADRs and AEs (Safety Specifications of the Survey related)	—

Countries

Japan

Contacts

Public ContactSatoshi KAMEYAMA

NIHON SERVIER CO., LTD. MEDICAL AFFAIRS

satoshi.kameyama@servier.com07024933214

Outcome results